User profiles for Magnus Gisslen
Magnus GisslénVerified email at infect.gu.se Cited by 16131 |
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19
…, RW Price, K Blennow, H Zetterberg, M Gisslén - Neurology, 2020 - AAN Enterprises
Objective To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …
[HTML][HTML] Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study
M Gisslén, RW Price, U Andreasson, N Norgren… - …, 2016 - thelancet.com
Background Cerebrospinal fluid (CSF) neurofilament light chain protein (NFL) is a sensitive
marker of neuronal injury in a variety of neurodegenerative conditions, including the CNS …
marker of neuronal injury in a variety of neurodegenerative conditions, including the CNS …
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment
…, B Svennerholm, RW Price, M Gisslén - Journal of Infectious …, 2010 - academic.oup.com
Background. Occasional cases of viral escape in cerebrospinal fluid (CSF) despite suppression
of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We …
of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We …
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
…, L Forsgren, JL Frederiksen, M Gisslén… - JAMA …, 2019 - jamanetwork.com
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …
number of neurological conditions compared with healthy controls (HC) and is a candidate …
[HTML][HTML] Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders
Background To accurately interpret COVID-19 seroprevalence surveys, knowledge of serum-IgG
responses to SARS-CoV-2 with a better understanding of patients who do not …
responses to SARS-CoV-2 with a better understanding of patients who do not …
[HTML][HTML] The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?
Background A substantial prevalence of mild neurocognitive disorders has been reported in
HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a …
HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a …
[HTML][HTML] COVIDENZA-A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus …
…, J Styrke, J Repo, ÅÖ Balkhed, K Niward, M Gisslén… - Trials, 2021 - Springer
Objectives The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone
signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. …
signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. …
[HTML][HTML] Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
Background Because of the emerging intersections of HIV infection and Alzheimer's disease,
we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism …
we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism …
[HTML][HTML] Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up
…, B Nellgård, K Blennow, H Zetterberg, M Gisslén - …, 2021 - thelancet.com
Background Neurologic manifestations are well-recognized features of coronavirus disease
2019 (COVID-19). However, the longitudinal association of biomarkers reflecting CNS …
2019 (COVID-19). However, the longitudinal association of biomarkers reflecting CNS …
Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load
…, J Peterson, E Lee, D Fuchs, A Boschini, M Gisslén… - Aids, 2012 - journals.lww.com
Objective: To characterize HIV-infected patients with neurosymptomatic cerebrospinal fluid (CSF)‘escape’,
defined as detectable CSF HIV RNA in the setting of treatment-suppressed …
defined as detectable CSF HIV RNA in the setting of treatment-suppressed …